Exact Mass: 727.5784286

Cerebroside B

C41H77NO9 (727.5598032)

Cerebroside B is found in mushrooms. Cerebroside B is from Clitocybe specie From Clitocybe subspecies Cerebroside B is found in mushrooms.

GlcCer(d18:1/18:0)

C42H81NO8 (727.5961866)

GlcCer(d18:1/18:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GL1a carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6\\% of the weight of lipids from brain, but they are found at low levels in all animal tissues.Cerebrosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Cerebrosides have a single sugar group linked to ceramide. The most common are galactocerebrosides (containing galactose), the least common are glucocerebrosides (containing glucose). Galactocerebrosides are found predominantly in neuronal cell membranes. In contrast glucocerebrosides are not normally found in membranes. Instead, they are typically intermediates in the synthesis or degradation of more complex glycosphingolipids. Galactocerebrosides are synthesized from ceramide and UDP-galactose. Excess lysosomal accumulation of glucocerebrosides is found in Gaucher disease. A glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GL1a carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6\\% of the weight of lipids from brain, but they are found at low levels in all animal tissues.

PE(18:1(11Z)/P-18:1(11Z))

C41H78NO7P (727.5515607999998)

PE(18:1(11Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:1(11Z)/P-18:1(11Z)), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(18:1(11Z)/P-18:1(9Z))

C41H78NO7P (727.5515607999998)

PE(18:1(11Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:1(11Z)/P-18:1(9Z)), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(18:1(9Z)/P-18:1(11Z))

C41H78NO7P (727.5515607999998)

PE(18:1(9Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:1(9Z)/P-18:1(11Z)), in particular, consists of one chain of oleic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The oleic acid moiety is derived from vegetable oils, especially olive and canola oil, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(18:1(9Z)/P-18:1(9Z))

C41H78NO7P (727.5515607999998)

PE(18:1(9Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:1(9Z)/P-18:1(9Z)), in particular, consists of one chain of oleic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The oleic acid moiety is derived from vegetable oils, especially olive and canola oil, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(18:2(9Z,12Z)/P-18:0)

C41H78NO7P (727.5515607999998)

PE(18:2(9Z,12Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:2(9Z,12Z)/P-18:0), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The linoleic acid moiety is derived from seed oils, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(18:2(9Z,12Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:2(9Z,12Z)/P-18:0), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The linoleic acid moiety is derived from seed oils, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(20:2(11Z,14Z)/P-16:0)

C41H78NO7P (727.5515607999998)

PE(20:2(11Z,14Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:2(11Z,14Z)/P-16:0), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The eicosadienoic acid moiety is derived from fish oils and liver, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:2(11Z,14Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:2(11Z,14Z)/P-16:0), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The eicosadienoic acid moiety is derived from fish oils and liver, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

CerP(d18:1/24:1(15Z))

C42H82NO6P (727.5879442)

CerP(d18:1/24:1(15Z)) is a ceramide 1-phosphate belonging to the sphingolipid class of molecules. Ceramides are amides of fatty acids with long-chain di- or trihydroxy bases, the commonest in animals being sphingosine and in plants phytosphingosine. The acyl group of ceramides is generally a long-chain saturated or monounsaturated fatty acid. The most frequent fatty acids found in animal ceramides are 18:0, 24:0 and 24:1(n-9). Ceramide 1-phosphates are produced by phosphorylation of ceramide by a specific ceramide kinase. Ceramide-1-phosphate was shown to be a specific and potent inducer of arachidonic acid and prostanoid synthesis in cells through the translocation and activation of the cytoplasmic phospholipase A2. [HMDB] CerP(d18:1/24:1(15Z)) is a ceramide 1-phosphate belonging to the sphingolipid class of molecules. Ceramides are amides of fatty acids with long-chain di- or trihydroxy bases, the commonest in animals being sphingosine and in plants phytosphingosine. The acyl group of ceramides is generally a long-chain saturated or monounsaturated fatty acid. The most frequent fatty acids found in animal ceramides are 18:0, 24:0 and 24:1(n-9). Ceramide 1-phosphates are produced by phosphorylation of ceramide by a specific ceramide kinase. Ceramide-1-phosphate was shown to be a specific and potent inducer of arachidonic acid and prostanoid synthesis in cells through the translocation and activation of the cytoplasmic phospholipase A2.

Galactosylceramide (d18:1/18:0)

C42H81NO8 (727.5961866)

Galactosylceramides (GalCer) are non-acidic monoglycosphingolipids, i.e. a sphingolipid with one carbohydrate moiety attached to a ceramide unit. They are an intermediate in sphingolipid metabolism and is the second to last step in the synthesis of digalactosylceramidesulfate. GalCer is generated from ceramide via the enzyme UDP-galactose ceramide galactosyltransferase [EC:2.4.1.47]. It can be converted to digalactosylceramide via the enzyme glycosyltransferases [EC 2.4.1.-]. Galactosylceramide is the principal glycosphingolipid in brain tissue, hence the trivial name "cerebroside", which was first conferred on it in 1874. Galactosylceramides are found in all nervous tissues, but they can amount to 2\\% of the dry weight of grey matter and 12\\% of white matter. They are major constituents of oligodendrocytes. Synthesis of galactosylceramide takes place on the lumenal surface of the endoplasmic reticulum, although it has free access to the cytosolic surface by an energy-independent flip-flop process. GalCer sits in the extracellular leaflet of cell membranes in nanometer sized domains or rafts. The local clustering of GalCer within rafts is thought to facilitate the initial adhesion of certain viruses, including HIV-1 and bacteria to cells through multivalent interactions between receptor proteins and GalCer. A defect in the degradation of cerbrosides leads to a disorder called Krabbe disease. Krabbe disease (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare, often fatal degenerative disorder that affects the myelin sheath of the nervous system. Krabbe disease is caused by mutations in the GALC gene, which causes a deficiency of galactosylceramidase. Infants with Krabbe disease are normal at birth. Symptoms begin between the ages of 3 and 6 months with irritability, fevers, limb stiffness, seizures, feeding difficulties, vomiting, and slowing of mental and motor development. There are also juvenile- and adult-onset cases of Krabbe disease, which have similar symptoms but slower progression. In infants, the disease is generally fatal before age 2. Patients with late-onset Krabbe disease tend to have a slower progression of the disease and live significantly longer.Cerebrosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Cerebrosides have a single sugar group linked to ceramide. The most common are galactocerebrosides (containing galactose), the least common are glucocerebrosides (containing glucose). Galactocerebrosides are found predominantly in neuronal cell membranes. In contrast glucocerebrosides are not normally found in membranes. Instead, they are typically intermediates in the synthesis or degradation of more complex glycosphingolipids. Galactocerebrosides are synthesized from ceramide and UDP-galactose. Excess lysosomal accumulation of glucocerebrosides is found in Gaucher disease. GGalactosylceramide (GalCer) is a non-acidic monoglycosphingolipid, i.e. a sphingolipid with one carbohydrate moiety attached to a ceramide unit. It is an intermediate in sphingolipid metabolism and is the second to last step in the synthesis of digalactosylceramidesulfate. GalCer is generated from ceramide via the enzyme UDP-galactose ceramide galactosyltransferase [EC:2.4.1.47]. It can be converted to digalactosylceramide via the enzyme glycosyltransferases [EC 2.4.1.-]. Galactosylceramide is the principal glycosphingolipid in brain tissue, hence the trivial name "cerebroside", which was first conferred on it in 1874. Galactosylceramides are found in all nervous tissues, but they can amount to 2\\% of the dry weight of grey matter and 12\\% of white matter. They are major constituents of oligodendrocytes. Synthesis of galactosylceramide takes place on the lumenal surface of the endoplasmic reticulum, although it has free access to the cytosolic surface by an energy-independent flip-flop process. GalCer sits in the extracellular leaflet of cell membranes in nanometer sized domains or rafts. The local clustering of GalCer within rafts is thought to facilitate the initial adhesion of certain viruses, including HIV-1 and bacteria to cells through multivalent interactions between receptor proteins and GalCer. A defect in the degradation of cerbrosides leads to a disorder called Krabbe disease. Krabbe disease (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare, often fatal degenerative disorder that affects the myelin sheath of the nervous system. Krabbe disease is caused by mutations in the GALC gene, which causes a deficiency of galactosylceramidase. Infants with Krabbe disease are normal at birth. Symptoms begin between the ages of 3 and 6 months with irritability, fevers, limb stiffness, seizures, feeding difficulties, vomiting, and slowing of mental and motor development. There are also juvenile- and adult-onset cases of Krabbe disease, which have similar symptoms but slower progression. In infants, the disease is generally fatal before age 2. Patients with late-onset Krabbe disease tend to have a slower progression of the disease and live significantly longer.

PC(P-16:0/P-18:1(11Z))

C42H82NO6P (727.5879442)

PC(P-16:0/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/P-18:1(11Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PC(P-16:0/P-18:1(9Z))

C42H82NO6P (727.5879442)

PC(P-16:0/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/P-18:1(9Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PC(P-18:1(11Z)/P-16:0)

C42H82NO6P (727.5879442)

PC(P-18:1(11Z)/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/P-16:0), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PC(P-18:1(9Z)/P-16:0)

C42H82NO6P (727.5879442)

PC(P-18:1(9Z)/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/P-16:0), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-16:0/20:2(11Z,14Z))

C41H78NO7P (727.5515607999998)

PE(P-16:0/20:2(11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/20:2(11Z,14Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of eicosadienoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the eicosadienoic acid moiety is derived from fish oils and liver. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-16:0/20:2(11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/20:2(11Z,14Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of eicosadienoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the eicosadienoic acid moiety is derived from fish oils and liver. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-18:0/18:2(9Z,12Z))

C41H78NO7P (727.5515607999998)

PE(P-18:0/18:2(9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/18:2(9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-18:1(11Z)/18:1(11Z))

C41H78NO7P (727.5515607999998)

PE(P-18:1(11Z)/18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/18:1(11Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of vaccenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the vaccenic acid moiety is derived from butter fat and animal fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(P-18:1(11Z)/18:1(9Z))

C41H78NO7P (727.5515607999998)

PE(P-18:1(11Z)/18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/18:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of oleic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(11Z)/18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/18:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of oleic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-18:1(9Z)/18:1(11Z))

C41H78NO7P (727.5515607999998)

PE(P-18:1(9Z)/18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/18:1(11Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of vaccenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the vaccenic acid moiety is derived from butter fat and animal fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(P-18:1(9Z)/18:1(9Z))

C41H78NO7P (727.5515607999998)

PE(P-18:1(9Z)/18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/18:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of oleic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(9Z)/18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/18:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of oleic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

Phosphatidylethanolamine alkenyl 18:0-18:2

C41H78NO7P (727.5515607999998)

Phosphatidylethanolamine alkenyl 18:1-18:1

C41H78NO7P (727.5515607999998)

Phosphatidylethanolamine alkenyl 16:0-20:2

C41H78NO7P (727.5515607999998)

1-O-beta-D-Galactopyranosyl-N-(2R-hydroxy-15-methylpalmitoyl)-sphinga-4E,8E-dienin

C41H77NO9 (727.5598032)

N-[3-hydroxy-1-{[3.4.5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octadec-4-en-2-yl]octadecanamide

C42H81NO8 (727.5961866)

(2-aminoethoxy)[2-[octadec-9-enoyloxy]-3-[octadeca-1.11-dien-1-yloxy]propoxy]phosphinic acid

C41H78NO7P (727.5515607999998)

GlcCer(d14:1/22:0)

C42H81NO8 (727.5961866)

GlcCer(d16:1/20:0)

C42H81NO8 (727.5961866)

GlcCer(d15:2(4E,6E)/20:0(2OH))

C41H77NO9 (727.5598032)

C24:1 CerP

C42H82NO6P (727.5879442)

C18 GlcCer

C42H81NO8 (727.5961866)

C18-Cerebroside

C42H81NO8 (727.5961866)

C18:1DH GlcCer

C42H81NO8 (727.5961866)

Galbeta-Cer(d18:1/18:0)

C42H81NO8 (727.5961866)

PE(36:2)

C41H78NO7P (727.5515607999998)

Glucosylceramide (d18:1/18:0)

C42H81NO8 (727.5961866)

Betaine lipid

C42H81NO8 (727.5961866)

PC(P-16:0/17:2(9Z,12Z))

C41H78NO7P (727.5515607999998)

PE(O-18:0/18:3(6Z,9Z,12Z))

C41H78NO7P (727.5515607999998)

PE(O-18:0/18:3(9Z,12Z,15Z))

C41H78NO7P (727.5515607999998)

PE(O-16:0/20:3(8Z,11Z,14Z))

C41H78NO7P (727.5515607999998)

cerebroside

C41H77NO9 (727.5598032)

DGCC 32:0

C42H81NO8 (727.5961866)

PC O-33:3

C41H78NO7P (727.5515607999998)

PE(P-18:0/18:2)

C41H78NO7P (727.5515607999998)

HexCer 35:2;O3

C41H77NO9 (727.5598032)

Chrysogeside E

C41H77NO9 (727.5598032)

A glucosylceramide isolated from Penicillium chrysogenum.

Cerebroside B

C41H77NO9 (727.5598032)

HexCer 36:1;O2

C42H81NO8 (727.5961866)

2-[hydroxy-[(4E,14E)-3-hydroxy-2-[[(E)-octadec-9-enoyl]amino]octadeca-4,14-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-azaniumylethyl (2R)-2-{[(9Z,12Z)-octadeca-9,12-dienoyl]oxy}-3-{[(1Z)-octadec-1-en-1-yl]oxy}propyl phosphate

C41H78NO7P (727.5515607999998)

beta-D-galactosyl-N-octadecanoylsphingosine

C42H81NO8 (727.5961866)

A beta-D-galactosyl-N-acylsphingosine in which the acyl group is specified as octadecanoyl.

PE(18:1(11Z)/P-18:1(11Z))

C41H78NO7P (727.5515607999998)

PE(18:1(11Z)/P-18:1(9Z))

C41H78NO7P (727.5515607999998)

N-stearoyl-D-galactosylsphingosine

C42H81NO8 (727.5961866)

N-tetracosanoylsphingosine 1-phosphate(2-)

C42H82NO6P-2 (727.5879442)

N-nonadecanoyl-1-O-beta-D-glucosyl-15-methylhexadecasphing-4-enine

C42H81NO8 (727.5961866)

2-[hydroxy-[(2S,3R)-3-hydroxy-2-(octadeca-3,6-dienoylamino)octadec-5-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(2S,3R,4E,14Z)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]octadeca-4,14-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]octadecanamide

C42H81NO8 (727.5961866)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (Z)-octadec-9-enoate

C41H78NO7P (727.5515607999998)

HexCer 31:1;2O/5:0

C42H81NO8 (727.5961866)

HexCer 8:1;2O/28:0

C42H81NO8 (727.5961866)

HexCer 32:1;2O/4:0

C42H81NO8 (727.5961866)

HexCer 9:1;2O/27:0

C42H81NO8 (727.5961866)

HexCer 33:1;2O/3:0

C42H81NO8 (727.5961866)

HexCer 30:1;2O/6:0

C42H81NO8 (727.5961866)

HexCer 27:1;2O/9:0

C42H81NO8 (727.5961866)

HexCer 34:1;2O/2:0

C42H81NO8 (727.5961866)

HexCer 8:0;2O/28:1

C42H81NO8 (727.5961866)

HexCer 29:1;2O/7:0

C42H81NO8 (727.5961866)

HexCer 28:1;2O/8:0

C42H81NO8 (727.5961866)

HexCer 11:1;2O/25:0

C42H81NO8 (727.5961866)

HexCer 19:0;2O/17:1

C42H81NO8 (727.5961866)

HexCer 13:1;2O/23:0

C42H81NO8 (727.5961866)

HexCer 10:0;2O/26:1

C42H81NO8 (727.5961866)

HexCer 23:0;2O/13:1

C42H81NO8 (727.5961866)

HexCer 14:0;2O/22:1

C42H81NO8 (727.5961866)

HexCer 15:0;2O/21:1

C42H81NO8 (727.5961866)

HexCer 10:1;2O/26:0

C42H81NO8 (727.5961866)

HexCer 26:1;2O/10:0

C42H81NO8 (727.5961866)

HexCer 20:0;2O/16:1

C42H81NO8 (727.5961866)

HexCer 12:0;2O/24:1

C42H81NO8 (727.5961866)

HexCer 12:1;2O/24:0

C42H81NO8 (727.5961866)

HexCer 25:1;2O/11:0

C42H81NO8 (727.5961866)

HexCer 18:0;2O/18:1

C42H81NO8 (727.5961866)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (22Z,25Z,28Z)-hexatriaconta-22,25,28-trienoate

C41H78NO7P (727.5515607999998)

HexCer 21:1;2O/14:1;O

C41H77NO9 (727.5598032)

HexCer 20:2;2O/15:0;O

C41H77NO9 (727.5598032)

HexCer 18:2;2O/17:0;O

C41H77NO9 (727.5598032)

HexCer 16:2;2O/19:0;O

C41H77NO9 (727.5598032)

HexCer 22:1;2O/13:1;O

C41H77NO9 (727.5598032)

HexCer 19:0;2O/16:2;O

C41H77NO9 (727.5598032)

HexCer 19:1;2O/16:1;O

C41H77NO9 (727.5598032)

HexCer 17:2;2O/18:0;O

C41H77NO9 (727.5598032)

HexCer 21:2;2O/14:0;O

C41H77NO9 (727.5598032)

HexCer 19:2;2O/16:0;O

C41H77NO9 (727.5598032)

HexCer 20:1;2O/15:1;O

C41H77NO9 (727.5598032)

HexCer 22:2;2O/13:0;O

C41H77NO9 (727.5598032)

HexCer 17:1;2O/18:1;O

C41H77NO9 (727.5598032)

HexCer 17:0;2O/18:2;O

C41H77NO9 (727.5598032)

HexCer 18:1;2O/17:1;O

C41H77NO9 (727.5598032)

HexCer 16:1;2O/19:1;O

C41H77NO9 (727.5598032)

[3-nonoxy-2-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

2-(3-Octanoyloxy-2-tetracosanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H81NO8 (727.5961866)

(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[(4E,8E,12E)-1,3-dihydroxynonadeca-4,8,12-trien-2-yl]triaconta-6,9,12,15,18,21,24,27-octaenamide

C49H77NO3 (727.5903132)

(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]dotriaconta-8,11,14,17,20,23,26,29-octaenamide

C49H77NO3 (727.5903132)

(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]dotriaconta-5,8,11,14,17,20,23,26,29-nonaenamide

C49H77NO3 (727.5903132)

2-(3-Nonanoyloxy-2-tricosanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H81NO8 (727.5961866)

(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]tetratriaconta-10,13,16,19,22,25,28,31-octaenamide

C49H77NO3 (727.5903132)

(9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]hexatriaconta-9,12,15,18,21,24,27,30,33-nonaenamide

C49H77NO3 (727.5903132)

(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-(1,3-dihydroxynonan-2-yl)tetraconta-7,10,13,16,19,22,25,28,31,34,37-undecaenamide

C49H77NO3 (727.5903132)

(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]tetraconta-10,13,16,19,22,25,28,31,34,37-decaenamide

C49H77NO3 (727.5903132)

(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]tetratriaconta-7,10,13,16,19,22,25,28,31-nonaenamide

C49H77NO3 (727.5903132)

2-[2,3-Di(hexadecanoyloxy)propoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H81NO8 (727.5961866)

2-(2-Henicosanoyloxy-3-undecanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H81NO8 (727.5961866)

2-(2-Nonadecanoyloxy-3-tridecanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H81NO8 (727.5961866)

2-(2-Octadecanoyloxy-3-tetradecanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H81NO8 (727.5961866)

2-(2-Heptadecanoyloxy-3-pentadecanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H81NO8 (727.5961866)

2-(3-Decanoyloxy-2-docosanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H81NO8 (727.5961866)

2-(3-Dodecanoyloxy-2-icosanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H81NO8 (727.5961866)

(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]hexatriaconta-6,9,12,15,18,21,24,27,30,33-decaenamide

C49H77NO3 (727.5903132)

(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]octatriaconta-8,11,14,17,20,23,26,29,32,35-decaenamide

C49H77NO3 (727.5903132)

3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]hexadecane-1-sulfonic acid

C42H81NO6S (727.5784286)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(14Z,17Z,20Z)-octacosa-14,17,20-trienoxy]propan-2-yl] octanoate

C41H78NO7P (727.5515607999998)

(E)-3-hydroxy-2-[[(Z)-2-hydroxydocos-11-enoyl]amino]icos-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

(E)-3-hydroxy-2-[[(Z)-2-hydroxyicos-11-enoyl]amino]docos-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

(E)-3-hydroxy-2-[[(Z)-2-hydroxyoctadec-11-enoyl]amino]tetracos-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxyhenicosanoylamino)henicosa-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(E)-3-hydroxy-2-[[(Z)-2-hydroxynonadec-9-enoyl]amino]tricos-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]tetracosane-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxyicosanoylamino)docosa-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]octadecane-1-sulfonic acid

C42H81NO6S (727.5784286)

3-hydroxy-2-[[(4Z,7Z)-2-hydroxyhexadeca-4,7-dienoyl]amino]hexacosane-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxyhexadecanoylamino)hexacosa-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxyhexacosanoylamino)hexadeca-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(E)-3-hydroxy-2-[[(Z)-2-hydroxypentacos-11-enoyl]amino]heptadec-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

3-hydroxy-2-[[(11Z,14Z)-2-hydroxyicosa-11,14-dienoyl]amino]docosane-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxytricosanoylamino)nonadeca-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxytetracosanoylamino)octadeca-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(E)-3-hydroxy-2-[[(Z)-2-hydroxyhexacos-11-enoyl]amino]hexadec-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

3-hydroxy-2-[[(14Z,16Z)-2-hydroxydocosa-14,16-dienoyl]amino]icosane-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxydocosanoylamino)icosa-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxyheptadecanoylamino)pentacosa-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(E)-3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]hexacos-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] (14Z,17Z,20Z)-octacosa-14,17,20-trienoate

C41H78NO7P (727.5515607999998)

(4E,8E)-3-hydroxy-2-(2-hydroxynonadecanoylamino)tricosa-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(E)-3-hydroxy-2-[[(Z)-2-hydroxyhenicos-9-enoyl]amino]henicos-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxypentacosanoylamino)heptadeca-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(E)-3-hydroxy-2-[[(Z)-2-hydroxytricos-11-enoyl]amino]nonadec-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

(4E,8E)-3-hydroxy-2-(2-hydroxyoctadecanoylamino)tetracosa-4,8-diene-1-sulfonic acid

C42H81NO6S (727.5784286)

(E)-3-hydroxy-2-[[(Z)-2-hydroxytetracos-11-enoyl]amino]octadec-4-ene-1-sulfonic acid

C42H81NO6S (727.5784286)

[3-[(14Z,17Z,20Z)-octacosa-14,17,20-trienoxy]-2-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[2-heptanoyloxy-3-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[2-nonanoyloxy-3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] (12Z,15Z,18Z)-hexacosa-12,15,18-trienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoxy]propan-2-yl] dodecanoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] (Z)-heptadec-9-enoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (10Z,13Z,16Z)-tetracosa-10,13,16-trienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] icosanoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] (Z)-nonadec-9-enoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-henicosa-11,14-dienoxy]propan-2-yl] (Z)-pentadec-9-enoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-icos-11-enoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-icosoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoxy]propan-2-yl] decanoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-docosa-13,16-dienoxy]propan-2-yl] (Z)-tetradec-9-enoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (Z)-hexadec-9-enoate

C41H78NO7P (727.5515607999998)

[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-tridecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[3-[(11Z,14Z)-icosa-11,14-dienoxy]-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-pentadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[2-heptadecanoyloxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[3-heptadecoxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[3-[(Z)-heptadec-9-enoxy]-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(Z)-hexadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-undecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[3-[(9Z,12Z)-nonadeca-9,12-dienoxy]-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

2-[4-[12-hydroxy-10,13-dimethyl-3-[(Z)-nonadec-9-enoyl]oxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid

C45H77NO6 (727.5750582000001)

HexCer 20:1;2O/16:0

C42H81NO8 (727.5961866)

HexCer 21:0;2O/15:1

C42H81NO8 (727.5961866)

HexCer 22:1;2O/14:0

C42H81NO8 (727.5961866)

HexCer 14:1;2O/22:0

C42H81NO8 (727.5961866)

HexCer 17:0;2O/19:1

C42H81NO8 (727.5961866)

HexCer 17:1;2O/19:0

C42H81NO8 (727.5961866)

HexCer 15:1;2O/21:0

C42H81NO8 (727.5961866)

HexCer 24:1;2O/12:0

C42H81NO8 (727.5961866)

HexCer 23:1;2O/13:0

C42H81NO8 (727.5961866)

HexCer 21:1;2O/15:0

C42H81NO8 (727.5961866)

HexCer 16:1;2O/20:0

C42H81NO8 (727.5961866)

HexCer 19:1;2O/17:0

C42H81NO8 (727.5961866)

HexCer 22:0;2O/14:1

C42H81NO8 (727.5961866)

HexCer 16:0;2O/20:1

C42H81NO8 (727.5961866)

CerP 16:1;2O/26:1

C42H82NO6P (727.5879442)

[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

C41H78NO7P (727.5515607999998)

[2-[(Z)-heptadec-9-enoyl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octadecoxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propan-2-yl] tetradecanoate

C41H78NO7P (727.5515607999998)

[3-[(9Z,12Z)-octadeca-9,12-dienoxy]-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (Z)-icos-11-enoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (13Z,16Z)-docosa-13,16-dienoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] hexadecanoate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] octadecanoate

C41H78NO7P (727.5515607999998)

[3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(Z)-hexadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C41H78NO7P (727.5515607999998)

[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

[3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H78NO7P (727.5515607999998)

(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetracosan-2-yl]dodec-5-enamide

C42H81NO8 (727.5961866)

(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradecan-2-yl]docos-11-enamide

C42H81NO8 (727.5961866)

(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytricosan-2-yl]tridec-8-enamide

C42H81NO8 (727.5961866)

(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosan-2-yl]hexadec-7-enamide

C42H81NO8 (727.5961866)

(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadecan-2-yl]henicos-9-enamide

C42H81NO8 (727.5961866)

(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]octadec-11-enamide

C42H81NO8 (727.5961866)

plasmenyl-PC 33:2

C41H78NO7P (727.5515607999998)

N-(tetradecanoyl)-1-beta-glucosyl-4E-docosasphingenine

C42H81NO8 (727.5961866)

N-(pentadecanoyl)-1-beta-glucosyl-4E-heneicosasphingenine

C42H81NO8 (727.5961866)

N-(hexadecanoyl)-1-beta-glucosyl-4E-eicosasphingenine

C42H81NO8 (727.5961866)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-8-en-2-yl]octadecanamide

C42H81NO8 (727.5961866)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C41H78NO7P (727.5515607999998)

2-[hydroxy-[(2S,3R,4E,6E)-3-hydroxy-2-[[(E)-icos-11-enoyl]amino]hexadeca-4,6-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(2S,3R,4E,6E)-2-[[(E)-docos-13-enoyl]amino]-3-hydroxytetradeca-4,6-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-4-en-2-yl]docosanamide

C42H81NO8 (727.5961866)

2-[[(2S,3R,4E,8E)-2-[[(E)-docos-13-enoyl]amino]-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

(E)-N-[(2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadecan-2-yl]heptadec-9-enamide

C42H81NO8 (727.5961866)

2-[[(2S,3R,4E,8E)-2-[[(E)-heptadec-9-enoyl]amino]-3-hydroxynonadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

[(E,2S,3R)-2-[[(E)-hexacos-17-enoyl]amino]-3-hydroxyhexadec-4-enyl] dihydrogen phosphate

C42H82NO6P (727.5879442)

N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicos-8-en-2-yl]pentadecanamide

C42H81NO8 (727.5961866)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadec-4-en-2-yl]nonadecanamide

C42H81NO8 (727.5961866)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadec-4-en-2-yl]henicosanamide

C42H81NO8 (727.5961866)

(E)-N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradecan-2-yl]docos-13-enamide

C42H81NO8 (727.5961866)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (5E,8E)-icosa-5,8-dienoate

C41H78NO7P (727.5515607999998)

N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicos-8-en-2-yl]hexadecanamide

C42H81NO8 (727.5961866)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-8-en-2-yl]heptadecanamide

C42H81NO8 (727.5961866)

(E)-N-[(2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosan-2-yl]hexadec-9-enamide

C42H81NO8 (727.5961866)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C41H78NO7P (727.5515607999998)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (11E,14E)-icosa-11,14-dienoate

C41H78NO7P (727.5515607999998)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-8-en-2-yl]docosanamide

C42H81NO8 (727.5961866)

2-[[(2S,3R,4E,8E)-2-[[(E)-hexadec-9-enoyl]amino]-3-hydroxyicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

[(E,2S,3R)-3-hydroxy-2-[[(E)-tetracos-15-enoyl]amino]octadec-4-enyl] dihydrogen phosphate

C42H82NO6P (727.5879442)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadec-8-en-2-yl]icosanamide

C42H81NO8 (727.5961866)

N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocos-8-en-2-yl]tetradecanamide

C42H81NO8 (727.5961866)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadec-8-en-2-yl]nonadecanamide

C42H81NO8 (727.5961866)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadec-4-en-2-yl]icosanamide

C42H81NO8 (727.5961866)

2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]octadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]heptadecanamide

C42H81NO8 (727.5961866)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C41H78NO7P (727.5515607999998)

(E)-N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadecan-2-yl]icos-11-enamide

C42H81NO8 (727.5961866)

2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C41H78NO7P (727.5515607999998)

2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(E)-icos-11-enoyl]amino]hexadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(2S,3R,4E,14E)-3-hydroxy-2-[[(E)-octadec-9-enoyl]amino]octadeca-4,14-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]octadecanamide

C42H81NO8 (727.5961866)

N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadec-8-en-2-yl]henicosanamide

C42H81NO8 (727.5961866)

2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(E)-octadec-9-enoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

(E)-N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]octadec-9-enamide

C42H81NO8 (727.5961866)

2-[[(4E,8E,12E)-2-(docosanoylamino)-3-hydroxytetradeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E)-2-[[(Z)-docos-11-enoyl]amino]-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]henicosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E,12E)-2-(henicosanoylamino)-3-hydroxypentadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E)-2-[[(Z)-hexadec-7-enoyl]amino]-3-hydroxyicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E,12E)-2-(heptadecanoylamino)-3-hydroxynonadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]docosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(E)-2-[[(14Z,16Z)-docosa-14,16-dienoyl]amino]-3-hydroxytetradec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-octadec-11-enoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E)-2-[[(Z)-dodec-5-enoyl]amino]-3-hydroxytetracosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E,12E)-2-(dodecanoylamino)-3-hydroxytetracosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(pentadecanoylamino)henicosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tridec-8-enoyl]amino]tricosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E)-2-[[(Z)-henicos-9-enoyl]amino]-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(tridecanoylamino)tricosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(octadecanoylamino)octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(nonadecanoylamino)heptadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(icosanoylamino)hexadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(E)-3-hydroxy-2-[[(10Z,12Z)-octadeca-10,12-dienoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]hexadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(tetradecanoylamino)docosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E,12E)-2-(hexadecanoylamino)-3-hydroxyicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(E)-2-[[(4Z,7Z)-hexadeca-4,7-dienoyl]amino]-3-hydroxyicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxytetradec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxynonadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(E)-2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E)-2-[[(Z)-docos-13-enoyl]amino]-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxypentadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E,12E)-2-acetamido-3-hydroxytetratriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E,12E)-2-(butanoylamino)-3-hydroxydotriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxytetradecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E)-2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxynonadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E,12E)-2-(decanoylamino)-3-hydroxyhexacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]dodec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E,12E)-2-(heptanoylamino)-3-hydroxynonacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[3-hydroxy-2-[[(14Z,17Z,20Z)-octacosa-14,17,20-trienoyl]amino]octoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]hexadecoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxyicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(propanoylamino)tritriaconta-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)pentacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E,12E)-2-(hexanoylamino)-3-hydroxytriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E)-2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(pentanoylamino)hentriaconta-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tricosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(nonanoylamino)heptacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[(4E,8E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]dodecoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxydecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(E)-3-hydroxy-2-[[(17Z,20Z)-octacosa-17,20-dienoyl]amino]oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(octanoylamino)octacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[[2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyicosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H80N2O6P+ (727.5753690000001)

beta-D-glucosyl-N-octadecanoylsphingosine

C42H81NO8 (727.5961866)

A beta-D-glucosyl-N-acylsphingosine in which the acyl group is specified as octadecanoyl.

CerP(d18:1/24:1(15Z))

C42H82NO6P (727.5879442)

1-(1Z-Octadecenyl)-2-linoleoyl-sn-glycero-3-phosphoethanolamine

C41H78NO7P (727.5515607999998)

A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkenyl and acyl groups are specified asas (1Z)-octadecenyl and linoleoyl respectively.

PE(P-18:1(9Z)/18:1(9Z))

C41H78NO7P (727.5515607999998)

PE(P-18:1(11Z)/18:1(9Z))

C41H78NO7P (727.5515607999998)

PE(P-16:0/20:2(11Z,14Z))

C41H78NO7P (727.5515607999998)

Galactosylceramide (d18:1/18:0)

C42H81NO8 (727.5961866)

PC(P-16:0/P-18:1(9Z))

C42H82NO6P (727.5879442)

PC(P-18:1(9Z)/P-16:0)

C42H82NO6P (727.5879442)

PC(P-16:0/P-18:1(11Z))

C42H82NO6P (727.5879442)

PC(P-18:1(11Z)/P-16:0)

C42H82NO6P (727.5879442)

PE(20:2(11Z,14Z)/P-16:0)

C41H78NO7P (727.5515607999998)

GlcCer(d18:2(4E,8Z)/17:0(2OH[R]))

C41H77NO9 (727.5598032)

N-tetracosanoylsphingosine 1-phosphate(2-)

C42H82NO6P (727.5879442)

A ceramide 1-phosphate(2-) in which the N-acyl group is specified as tetracosanoyl.

1-[(1Z,11Z)-octadecadienyl]-2-oleoyl-sn-glycero-3-phosphoethanolamine

C41H78NO7P (727.5515607999998)

A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alk-1-enyl and acyl groups are specified as (1Z,11Z)-octadecadienyl and oleoyl respectively.

1-(1Z-octadecenyl)-2-linoleoyl-sn-glycero-3-phosphoethanolamine zwitterion

C41H78NO7P (727.5515607999998)

A 1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alkenyl and acyl groups are specified as (1Z)-octadecenyl and linoleoyl respectively.

N-[(15Z)-tetracosenoyl]sphingosine 1-phosphate

C42H82NO6P (727.5879442)

An N-acylsphingosine 1-phosphate in which the N-acyl group is specified as (15Z)-tetracosenoyl.

Hex1Cer(36:1)

C42H81NO8 (727.5961866)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

MePC(32:3)

C41H78NO7P (727.5515607999998)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

dMePE(34:3)

C41H78NO7P (727.5515607999998)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

CerP(41:3)

C41H78NO7P (727.5515607999998)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

Hex1Cer(35:2)

C41H77NO9 (727.5598032)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

DGCC 31:1;O

C41H77NO9 (727.5598032)

DGTS 31:1;O2

C41H77NO9 (727.5598032)

DGTS 32:0;O

C42H81NO8 (727.5961866)

PC O-15:1/18:2

C41H78NO7P (727.5515607999998)

PC O-16:1/17:2

C41H78NO7P (727.5515607999998)

PC O-16:2/17:1

C41H78NO7P (727.5515607999998)

PC O-18:2/15:1

C41H78NO7P (727.5515607999998)

PC P-15:0/18:2

C41H78NO7P (727.5515607999998)

PC P-15:0/18:2 or PC O-15:1/18:2

C41H78NO7P (727.5515607999998)

PC P-16:0/17:2

C41H78NO7P (727.5515607999998)

PC P-16:0/17:2 or PC O-16:1/17:2

C41H78NO7P (727.5515607999998)

PC P-16:1/17:1

C41H78NO7P (727.5515607999998)

CerP 14:2;O2/28:0

C42H82NO6P (727.5879442)

CerP 15:2;O2/27:0

C42H82NO6P (727.5879442)

CerP 16:0;O2/26:2

C42H82NO6P (727.5879442)

CerP 16:1;O2/26:1

C42H82NO6P (727.5879442)

CerP 16:2;O2/26:0

C42H82NO6P (727.5879442)

CerP 17:2;O2/25:0

C42H82NO6P (727.5879442)

CerP 18:1;O2/24:1

C42H82NO6P (727.5879442)

CerP 18:2;O2/24:0

C42H82NO6P (727.5879442)

CerP 19:2;O2/23:0

C42H82NO6P (727.5879442)

CerP 20:0;O2/22:2

C42H82NO6P (727.5879442)

CerP 20:1;O2/22:1

C42H82NO6P (727.5879442)

CerP 20:2;O2/22:0

C42H82NO6P (727.5879442)

CerP 21:2;O2/21:0

C42H82NO6P (727.5879442)

CerP 22:0;O2/20:2

C42H82NO6P (727.5879442)

CerP 22:1;O2/20:1

C42H82NO6P (727.5879442)

CerP 22:2;O2/20:0

C42H82NO6P (727.5879442)

GalCer 14:0;O2/22:1

C42H81NO8 (727.5961866)

GalCer 14:1;O2/22:0

C42H81NO8 (727.5961866)

GalCer 14:2;O2/21:0;O

C41H77NO9 (727.5598032)

GalCer 15:0;O3/20:2

C41H77NO9 (727.5598032)

GalCer 15:1;O2/20:1;O

C41H77NO9 (727.5598032)

GalCer 15:1;O2/21:0

C42H81NO8 (727.5961866)

GalCer 15:2;O2/20:0;O

C41H77NO9 (727.5598032)

GalCer 16:0;O2/20:1

C42H81NO8 (727.5961866)

GalCer 16:1;O2/20:0

C42H81NO8 (727.5961866)

GalCer 16:2;O2/19:0;O

C41H77NO9 (727.5598032)

GalCer 17:0;O3/18:2

C41H77NO9 (727.5598032)

GalCer 17:1;O2/18:1;O

C41H77NO9 (727.5598032)

GalCer 17:1;O2/19:0

C42H81NO8 (727.5961866)

GalCer 17:2;O2/18:0;O

C41H77NO9 (727.5598032)

GalCer 18:0;O2/18:1

C42H81NO8 (727.5961866)

GalCer 18:0;O3/17:2

C41H77NO9 (727.5598032)

GalCer 18:1;O2/18:0

C42H81NO8 (727.5961866)

GalCer 18:2;O2/17:0;O

C41H77NO9 (727.5598032)

GalCer 19:0;O2/17:1

C42H81NO8 (727.5961866)

GalCer 19:1;O2/17:0

C42H81NO8 (727.5961866)

GalCer 19:2;O2/16:0;O

C41H77NO9 (727.5598032)

GalCer 20:0;O2/16:1

C42H81NO8 (727.5961866)

GalCer 20:1;O2/16:0

C42H81NO8 (727.5961866)

GalCer 20:2;O2/15:0;O

C41H77NO9 (727.5598032)

GalCer 21:0;O2/15:1

C42H81NO8 (727.5961866)

GalCer 21:1;O2/15:0

C42H81NO8 (727.5961866)

GalCer 21:2;O2/14:0;O

C41H77NO9 (727.5598032)

GalCer 22:0;O2/14:1

C42H81NO8 (727.5961866)

GalCer 22:1;O2/14:0

C42H81NO8 (727.5961866)

GalCer 22:2;O2/13:0;O

C41H77NO9 (727.5598032)

GalCer 35:2;O2;O

C41H77NO9 (727.5598032)

GalCer 35:2;O3

C41H77NO9 (727.5598032)

GalCer 36:1;O2

C42H81NO8 (727.5961866)

GlcCer 14:0;O2/22:1

C42H81NO8 (727.5961866)

GlcCer 14:1;O2/22:0

C42H81NO8 (727.5961866)

GlcCer 14:2;O2/21:0;O

C41H77NO9 (727.5598032)

GlcCer 15:0;O3/20:2

C41H77NO9 (727.5598032)

GlcCer 15:1;O2/20:1;O

C41H77NO9 (727.5598032)

GlcCer 15:1;O2/21:0

C42H81NO8 (727.5961866)

GlcCer 15:2;O2/20:0;O

C41H77NO9 (727.5598032)

GlcCer 15:2;O2(4E,6E)/20:0;O

C41H77NO9 (727.5598032)

GlcCer 16:0;O2/20:1

C42H81NO8 (727.5961866)

GlcCer 16:1;O2/20:0

C42H81NO8 (727.5961866)

GlcCer 16:2;O2/19:0;O

C41H77NO9 (727.5598032)

GlcCer 17:0;O3/18:2

C41H77NO9 (727.5598032)

GlcCer 17:1;O2/18:1;O

C41H77NO9 (727.5598032)

GlcCer 17:1;O2/19:0

C42H81NO8 (727.5961866)

GlcCer 17:2;O2/18:0;O

C41H77NO9 (727.5598032)

GlcCer 18:0;O2/18:1

C42H81NO8 (727.5961866)

GlcCer 18:0;O3/17:2

C41H77NO9 (727.5598032)

GlcCer 18:1;O2/18:0

C42H81NO8 (727.5961866)

GlcCer 18:2;O2/17:0;O

C41H77NO9 (727.5598032)

GlcCer 19:0;O2/17:1

C42H81NO8 (727.5961866)

GlcCer 19:1;O2/17:0

C42H81NO8 (727.5961866)

GlcCer 19:2;O2/16:0;O

C41H77NO9 (727.5598032)

GlcCer 20:0;O2/16:1

C42H81NO8 (727.5961866)

GlcCer 20:1;O2/16:0

C42H81NO8 (727.5961866)

GlcCer 20:2;O2/15:0;O

C41H77NO9 (727.5598032)

GlcCer 21:0;O2/15:1

C42H81NO8 (727.5961866)

GlcCer 21:1;O2/15:0

C42H81NO8 (727.5961866)

GlcCer 21:2;O2/14:0;O

C41H77NO9 (727.5598032)

GlcCer 22:0;O2/14:1

C42H81NO8 (727.5961866)

GlcCer 22:1;O2/14:0

C42H81NO8 (727.5961866)

GlcCer 22:2;O2/13:0;O

C41H77NO9 (727.5598032)

GlcCer 35:2;O2;O

C41H77NO9 (727.5598032)

GlcCer 35:2;O3

C41H77NO9 (727.5598032)

GlcCer 36:1;O2

C42H81NO8 (727.5961866)

HexCer 14:0;O2/22:1

C42H81NO8 (727.5961866)

HexCer 14:2;O2/21:0;2OH

C41H77NO9 (727.5598032)

HexCer 14:2;O2/21:0;3OH

C41H77NO9 (727.5598032)

HexCer 14:2;O2/21:0;O

C41H77NO9 (727.5598032)

HexCer 15:0;O3/20:2

C41H77NO9 (727.5598032)

HexCer 15:1;O2/20:1;2OH

C41H77NO9 (727.5598032)

HexCer 15:1;O2/20:1;3OH

C41H77NO9 (727.5598032)

HexCer 15:1;O2/20:1;O

C41H77NO9 (727.5598032)

HexCer 15:1;O2/21:0

C42H81NO8 (727.5961866)

HexCer 15:2;O2/20:0;2OH

C41H77NO9 (727.5598032)

HexCer 15:2;O2/20:0;3OH

C41H77NO9 (727.5598032)

HexCer 15:2;O2/20:0;O

C41H77NO9 (727.5598032)

HexCer 16:0;O2/20:1

C42H81NO8 (727.5961866)

HexCer 16:1;O2/20:0

C42H81NO8 (727.5961866)

HexCer 16:2;O2/19:0;2OH

C41H77NO9 (727.5598032)

HexCer 16:2;O2/19:0;3OH

C41H77NO9 (727.5598032)

HexCer 16:2;O2/19:0;O

C41H77NO9 (727.5598032)

HexCer 17:0;O3/18:2

C41H77NO9 (727.5598032)

HexCer 17:1;O2/18:1;2OH

C41H77NO9 (727.5598032)

HexCer 17:1;O2/18:1;3OH

C41H77NO9 (727.5598032)

HexCer 17:1;O2/18:1;O

C41H77NO9 (727.5598032)

HexCer 17:1;O2/19:0

C42H81NO8 (727.5961866)

HexCer 17:2;O2/18:0;2OH

C41H77NO9 (727.5598032)

HexCer 17:2;O2/18:0;3OH

C41H77NO9 (727.5598032)

HexCer 17:2;O2/18:0;O

C41H77NO9 (727.5598032)

HexCer 18:0;O2/18:1

C42H81NO8 (727.5961866)

HexCer 18:0;O3/17:2

C41H77NO9 (727.5598032)

HexCer 18:1;O2/18:0

C42H81NO8 (727.5961866)

HexCer 18:2;O2/17:0;2OH

C41H77NO9 (727.5598032)

HexCer 18:2;O2/17:0;3OH

C41H77NO9 (727.5598032)

HexCer 18:2;O2/17:0;O

C41H77NO9 (727.5598032)

HexCer 19:0;O2/17:1

C42H81NO8 (727.5961866)

HexCer 19:1;O2/17:0

C42H81NO8 (727.5961866)

HexCer 19:2;O2/16:0;2OH

C41H77NO9 (727.5598032)

HexCer 19:2;O2/16:0;3OH

C41H77NO9 (727.5598032)

HexCer 19:2;O2/16:0;O

C41H77NO9 (727.5598032)

HexCer 20:0;O2/16:1

C42H81NO8 (727.5961866)

HexCer 20:1;O2/16:0

C42H81NO8 (727.5961866)

HexCer 20:2;O2/15:0;2OH

C41H77NO9 (727.5598032)

HexCer 20:2;O2/15:0;3OH

C41H77NO9 (727.5598032)

HexCer 20:2;O2/15:0;O

C41H77NO9 (727.5598032)

HexCer 21:0;O2/15:1

C42H81NO8 (727.5961866)

HexCer 21:1;O2/15:0

C42H81NO8 (727.5961866)

HexCer 21:2;O2/14:0;2OH

C41H77NO9 (727.5598032)

HexCer 21:2;O2/14:0;3OH

C41H77NO9 (727.5598032)

HexCer 21:2;O2/14:0;O

C41H77NO9 (727.5598032)

HexCer 22:0;O2/14:1

C42H81NO8 (727.5961866)

HexCer 22:1;O2/14:0

C42H81NO8 (727.5961866)

HexCer 22:2;O2/13:0;2OH

C41H77NO9 (727.5598032)

HexCer 22:2;O2/13:0;3OH

C41H77NO9 (727.5598032)

HexCer 22:2;O2/13:0;O

C41H77NO9 (727.5598032)

HexCer 35:2;O2;O

C41H77NO9 (727.5598032)

GDCAE 19:1

C45H77NO6 (727.5750582000001)

(2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadeca-4,8-dien-2-yl]nonadecanimidic acid

C41H77NO9 (727.5598032)

(4E,8E)-N-D-2'-hydroxypalmitoyl-1-O-β-D-glucopyranosyl-9-methyl-4,8-spingodienine

C41H77NO9 (727.5598032)

{"Ingredient_id": "HBIN010345","Ingredient_name": "(4E,8E)-N-D-2'-hydroxypalmitoyl-1-O-\u03b2-D-glucopyranosyl-9-methyl-4,8-spingodienine","Alias": "NA","Ingredient_formula": "C41H77NO9","Ingredient_Smile": "CCCCCCCCCCCCCCC(C(=O)NC(COC1C(C(C(C(O1)CO)O)O)O)C(C=CCCC=C(C)CCCCCCCCC)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "37169","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

2-hydroxy-n-[(5e,9z)-3-hydroxy-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}nonadeca-5,9-dien-2-yl]hexadecanimidic acid

C41H77NO9 (727.5598032)

2-hydroxy-n-(3-hydroxy-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}nonadeca-5,9-dien-2-yl)hexadecanimidic acid

C41H77NO9 (727.5598032)

2-hydroxy-n-(3-hydroxy-9-methyl-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octadeca-4,8-dien-2-yl)hexadecanimidic acid

C41H77NO9 (727.5598032)

2-hydroxy-n-(3-hydroxy-9-methyl-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentadeca-4,8-dien-2-yl)nonadecanimidic acid

C41H77NO9 (727.5598032)

(2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-1-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octadeca-4,8-dien-2-yl]-15-methylhexadecanimidic acid

C41H77NO9 (727.5598032)

2-hydroxy-n-(3-hydroxy-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octadeca-4,8-dien-2-yl)-15-methylhexadecanimidic acid

C41H77NO9 (727.5598032)

(2r)-2-hydroxy-n-[(2r,3s,4e,8e)-3-hydroxy-9-methyl-1-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}octadeca-4,8-dien-2-yl]hexadecanimidic acid

C41H77NO9 (727.5598032)